Skip to content
Screener

Twist Bioscience Corporation TWST Reportable Segment — Litigation settlement costs, net of recoveries

Similar metrics at other companies

Napco Security Technologies logo
NSSCSingle Reportable — Litigation Settlement Expense
$16M
Aeva Technologies logo
AEVAReportable Segment Aggregation Before Other Operating — Litigation Settlement Expense
$0-100%
Sarepta Therapeutics, Inc. logo
SRPTAll Other Segments — Litigation Settlement Expense
$39M
IDT Corporation logo
IDTNRS — Litigation Settlement Expense
$600K
FreightCar America logo
RAILLeasing Revenues — Litigation Settlement Expense
$346.5K0.0%
IDT Corporation logo
IDTCorporate And Other — Litigation Settlement Expense
$400K

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:LitigationSettlementExpense.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(In thousands, except per share data)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
Cost of revenues$53,593$46,765$103,319$92,638
Research and development expenses19,69523,91736,82545,224
Selling, general and administrative expenses[1]76,08563,671145,827119,849
Litigation settlement costs, net of recoveries7,2057,205
Total costs and expenses$156,578$134,353$293,176$257,711
Loss from operations$(45,863)$(41,560)$(78,763)$(76,205)
Interest income1,7102,8013,8856,041
Other income (expense), net[1]175(394)646(487)

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's reportable segment — litigation settlement costs, net of recoveries?
Twist Bioscience Corporation (TWST) reported reportable segment — litigation settlement costs, net of recoveries of $7.21M in Q1 2026.
What does reportable segment — litigation settlement costs, net of recoveries mean?
Reflects the net financial impact of legal disputes, settlements, or recoveries specifically associated with the reportable segment. This metric highlights potential legal risks and the financial volatility associated with the segment's regulatory or competitive environment.

Ask your AI about Twist Bioscience Corporation's reportable segment — litigation settlement costs, net of recoveries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude